Many of these patients will be too sick to tolerate the CS procedure. That was underscored in the Delcath clinical trial where only 7 of the 93 patients enrolled had an ECOG performance status of 1 on a physical evaluation scale that ranges from 0-4. The rest of the patients in the study were ECOG status 0, or the "healthiest" of cancer patients.
Cutaneous melanoma is more commonly diagnosed but cases where metastatic disease is confined to the liver are exceedingly rare. Again, the Delcath study proves that, with only 12% of the patients enrolled fitting this category. (The rest of the patients had ocular melanoma.) It took years for Delcath to find the 11 cutaneous melanoma patients to enroll in the study.
Throw it all together and Delcath is looking at peak ocular melanoma sales of the CS system in the range of $25 million to $38 million. Throw in another $10 million in cutaneous melanoma sales for good measure and round up with a heavy thumb on the scale: $50 million.
Discount those $50 million in sales back a couple of years at a price-to-sales multiple of six and Delcath is worth $5-7 a share. Included in that estimate is partial credit for expanding CS into neuroendocrine and/or primary liver tumors.Let me put the valuation question another way: In order to justify Delcath at $10, the CS procedure would have to net about $130 million in sales. To justify Delcath's recent high of $16, CS peak sales would need to reach about $225 million. Delcath executives say the total melanoma market opportunity is almost $800 million with a long-term market opportunity growing to almost $7 billion. To me, those numbers are just nuts. Delcath has plans on international sales, but without survival data, regulators in Europe are going to give CS a rough time. Pricing and reimbursement issues are also more complicated in Europe and Asia.
Lisa K. asks, "Who were your winner and losers at ASCO this year?" Two easily identifiable winners: Bristol-Myers Squibb (BMY) and Celgene (CELG). The former grabbed the biggest headlines for the melanoma drug ipilimumab; the latter scored big with data establishing a new standard of care for multiple myeloma patients treated long-term with Revlimid as maintenance therapy.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV